Treatment with sodium- glucose cotransporter 2 (SGLT-2) inhibitors reduces the risk of hospitalization for heart failure (hHF) and death compared with other glucose-lowering drugs, the retrospective, observational CVD-REAL* study has shown.
Adding the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab to statin therapy to further lower bad cholesterol does not cause memory loss or other cognitive issues in patients with known cardiovascular disease (CVD), the EBBINGHAUS* trial has shown, giving clinicians some sense of reassurance.
The everolimus-eluting bioresorbable vascular scaffold (BVS), Absorb, was noninferior to Xience metal stent for target lesion failure (TLF) by 1 year and between 1–2 years, but was associated with significantly higher cumulative TLF rates by 25 months, according to the ABSORB III trial presented at the ACC.17 in Washington, DC, US.
The use of uninterrupted dabigatran before, during, and after catheter ablation in patients with atrial fibrillation (AF) resulted in fewer major bleeding complications than uninterrupted warfarin, according to results of the RE-CIRCUIT* trial.
Transcatheter aortic valve replacement (TAVR) is an effective and safe alternative to surgical aortic valve replacement (SAVR) for intermediate- and high-risk patients in the real world, with no significant difference in stroke and mortality rates at 1 year, and discharge to home being more common among TAVR patients, according to the ADVICE* study presented at the recent ACC.17 Scientific Session held in Washington, DC, US.
Noninvasive magnetic resonance (MR) perfusion imaging may be effective as initial guided management in patients with stable angina and intermediate-to-high risk for coronary artery disease (CAD) compared with invasive angiography and fractional flow reserve (FFR), according to the MR-INFORM* trial presented at the American College of Cardiology’s 66th Annual Scientific Session (ACC.17) held in Washington, DC, US.
Extended therapy with rivaroxaban was more effective than aspirin in reducing the risk of recurrent venous thromboembolism (VTE) with no significant increase in bleeding risk, according to data from the EINSTEIN CHOICE* study presented at the ACC.17 Scientific Session in Washington, DC, US.